CD274 and neoplasm: However, its role as a biomarker remains controversial, with confounding variables including differential sensitivities between the multiple immunohistochemistry assays, differences in PD-L1 positivity cutoff values, cell types included in the scoring (tumor ± immune cells), intra-tumoral heterogeneity, and biopsy timing and specimen quality [117].